Results 71 to 80 of about 172,168 (267)
Bone marrow‐like viscosity affects imatinib resistance in chronic myeloid leukemia
Physical cues such as microenvironmental viscosity have been recognized as important regulators in controlling cell functions. However, even though the bone marrow (BM) is a viscous tissue in which cells respond mechanically to both the matrix stiffness and the viscosity of surrounding fluid, the impact of microenvironmental viscosity on imatinib (IM ...
Tianjiao Zeng +6 more
wiley +1 more source
Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]
Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation.
Tara Ann Burns +9 more
doaj +1 more source
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo +10 more
wiley +1 more source
Non‐animal extracellular vesicles as bioactive‐compound carriers: compositional characteristics, engineering strategies, and biofunctions. Abstract Animal‐derived extracellular vesicles (EVs) were widely used for bioactive compound delivery but constrained by complex origins, potential immunogenicity, and pathogen contamination.
Jiahao Yu +6 more
wiley +1 more source
Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Jørgensen, Heather G. +24 more
core +1 more source
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells
Background The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of ...
Chai Juin Hsien +5 more
doaj +1 more source
Cross‐Platform Comparison of Chemoproteomics Workflows: Orbitrap‐TMT Versus timsTOF‐diaPASEF
ABSTRACT Chemoproteomics aims to achieve precise and comprehensive quantification of protein–small molecule interactions, yet methodological comparisons across quantitative proteomics workflows remain scarce. Here, we systematically benchmark tandem mass tag data‐dependent acquisition (TMT‐DDA) on Orbitrap Exploris/Eclipse instruments against label ...
Ursula M. Glocker +7 more
wiley +1 more source
The regulation of bcr-abl in hypoxia is through the mTOR pathway
Chronic myeloid leukemia (CML) is usually characterized by the formation of the fusion onco-protein bcr-abl. Therefore, the majority of CML treatments are bcr-abl specific tyrosine kinase inhibitors (TKIs).
Di Trapani, Giovanna +5 more
core +1 more source
Background The bcr-abl fusion gene is the pathological origin of chronic myeloid leukemia (CML) and plays a critical role in the resistance of imatinib. Thus, bcr-abl disruption-based novel therapeutic strategy may warrant exploration.
Ningshu Huang +8 more
doaj +1 more source
Neue Ansätze des molekularen Targetings bei der Philadelphia-Chromosom-positiven Leukämie [PDF]
In Philadelphia Chromosome (Ph) positive ALL and CML the fusion between BCR and ABL leads to the BCR/ABL fusion proteins, which induces the leukemic phenotype because of the constitutive activation of multiple signaling pathways down-stream to the ...
Mian, Afsar Ali
core

